Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Northwest Biotherapeutics (NWBO) Construction in Progress: 2009-2017

Historic Construction in Progress for Northwest Biotherapeutics (NWBO) over the last 1 years, with Dec 2017 value amounting to $47.3 million.

  • Northwest Biotherapeutics' Construction in Progress rose 6.19% to $47.3 million in Q4 2017 from the same period last year, while for Dec 2017 it was $47.3 million, marking a year-over-year increase of 6.19%. This contributed to the annual value of $47.3 million for FY2017, which is 6.19% up from last year.
  • Northwest Biotherapeutics' Construction in Progress amounted to $47.3 million in Q4 2017, which was down 0.01% from $47.3 million recorded in Q3 2017.
  • Over the past 5 years, Northwest Biotherapeutics' Construction in Progress peaked at $47.3 million during Q3 2017, and registered a low of $44.6 million during Q4 2016.
  • In the last 3 years, Northwest Biotherapeutics' Construction in Progress had a median value of $46.0 million in 2015 and averaged $46.0 million.
  • Its Construction in Progress has fluctuated over the past 5 years, first dropped by 2.46% in 2016, then rose by 6.19% in 2017.
  • Quarterly analysis of 3 years shows Northwest Biotherapeutics' Construction in Progress stood at $45.7 million in 2015, then fell by 2.46% to $44.6 million in 2016, then rose by 6.19% to $47.3 million in 2017.
  • Its last three reported values are $47.3 million in Q4 2017, $47.3 million for Q3 2017, and $46.2 million during Q2 2017.